Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$3.45 USD
-0.05 (-1.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.47 +0.02 (0.58%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth A Momentum B VGM
Income Statements
Fiscal Year end for Galectin Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 38 | 38 | 30 | 23 | 13 |
Income After Depreciation & Amortization | -38 | -38 | -30 | -23 | -13 |
Non-Operating Income | 0 | 1 | 0 | 0 | 0 |
Interest Expense | 3 | 1 | 0 | 0 | 0 |
Pretax Income | -41 | -39 | -31 | -23 | -13 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -41 | -39 | -31 | -23 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -41 | -39 | -31 | -23 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -38 | -38 | -30 | -23 | -13 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -38 | -38 | -30 | -23 | -13 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 60.16 | 59.39 | 58.53 | 57.03 | 52.24 |
Diluted EPS Before Non-Recurring Items | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 |
Diluted Net EPS (GAAP) | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 |
Fiscal Year end for Galectin Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 9.56 | 9.16 | 9.00 | 10.34 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.56 | -9.16 | -9.00 | -10.34 |
Non-Operating Income | NA | 0.41 | -0.43 | 0.54 | -0.73 |
Interest Expense | NA | 0.85 | 0.84 | 0.65 | 0.46 |
Pretax Income | NA | -10.00 | -10.43 | -9.11 | -11.53 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -10.00 | -10.43 | -9.11 | -11.53 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -10.00 | -10.43 | -9.11 | -11.53 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 62.21 | 59.70 | 59.58 | 59.48 |
Diluted EPS Before Non-Recurring Items | NA | -0.16 | -0.24 | -0.15 | -0.19 |
Diluted Net EPS (GAAP) | NA | -0.16 | -0.24 | -0.15 | -0.19 |